4 results about "Pyrimidine analogue" patented technology

The present invention relates to Compounds of Formula I: and pharmaceutically acceptable salts or prodrug thereof. The present invention also relates to compositions comprising at least one compound of Formula I, and methods of using the compounds of Formula I for treatment or prophylaxis of lysosomal storage diseases, neurodegenerative disease, cystic disease, cancer, or a diseases or disorders associated with elevated levels of glucosylceramide (GlcCer), glucosylsphingosine (GlcSph) and / or other glucosylceramide-based glycosphingolipids (GSLs).

Disclosed are combinations comprising a therapeutically effective amount of a menin-MLL inhibitor of Formula (I) or a pharmaceutically acceptable salt or a solvate thereof; and a therapeutically effective amount of at least one other therapeutic agent which is a hypomethylating agent, a cytidine deaminase inhibitor, a DNA intercalating agent, a pyrimidine analog, a purine analog, a kinase inhibitor, a CD20 inhibitor, an IDH inhibitor, an immunomodulatory agent or a DHODH inhibitor. Also disclosed are methods for treating a subject who has been diagnosed with cancer using such combinations. Compounds are represented by Formula (I) as follows:wherein the variables are defined herein.

The present invention relates generally to the fields of cancer cell biology, cancer therapeutics for cancers located within in the central nervous system, thymidine analogs and cellular nucleotide excision repair mechanisms. More specifically, the invention relates to the use of EdU in methods of treating cancers located within in the central nervous system, and methods of inhibiting and / or reducing growth of a cancer or cancer cell.

Compounds of the Formula (I), pharmaceutical compositions comprising compounds of the Formula (I), and their use for treating or preventing a viral infection: